[go: up one dir, main page]

EA199800882A1 - Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно) - Google Patents

Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)

Info

Publication number
EA199800882A1
EA199800882A1 EA199800882A EA199800882A EA199800882A1 EA 199800882 A1 EA199800882 A1 EA 199800882A1 EA 199800882 A EA199800882 A EA 199800882A EA 199800882 A EA199800882 A EA 199800882A EA 199800882 A1 EA199800882 A1 EA 199800882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pde
tnf
necrosis factor
formula
photophodiesterrase
Prior art date
Application number
EA199800882A
Other languages
English (en)
Other versions
EA002272B1 (ru
Inventor
Энтони Марфат
Original Assignee
Пфайзер Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк filed Critical Пфайзер Инк
Publication of EA199800882A1 publication Critical patent/EA199800882A1/ru
Publication of EA002272B1 publication Critical patent/EA002272B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы (I) и их фармацевтически приемлемым солям, где R и Rтакие, как определены здесь, Rвыбран из группы, состоящей из (Iа), (Iб, (Iв) и (Iг). Кроме того, изобретение относится к промежуточным соединениям для получения соединений формулы (I) и к фармацевтическим композициям, содержащим соединения формулы (I) или их фармацевтически приемлемые соли, и к способам применения соединений формулы (I) или их фармацевтически приемлемых солей для ингибирования фосфодиэстеразы (ФДЭ) типа IV или продукции фактора некроза опухолей (ФНО) у млекопитающих.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800882A 1996-05-03 1997-04-01 Производные замещенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продукции фактора некроза опухолей (фно) EA002272B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
EA199800882A1 true EA199800882A1 (ru) 1999-06-24
EA002272B1 EA002272B1 (ru) 2002-02-28

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800882A EA002272B1 (ru) 1996-05-03 1997-04-01 Производные замещенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продукции фактора некроза опухолей (фно)

Country Status (42)

Country Link
US (2) US6211222B1 (ru)
EP (1) EP0912521B1 (ru)
JP (1) JP3148254B2 (ru)
KR (1) KR100339935B1 (ru)
CN (2) CN1112359C (ru)
AP (4) AP2001002304A0 (ru)
AR (1) AR006906A1 (ru)
AT (1) ATE292626T1 (ru)
AU (1) AU725576B2 (ru)
BG (1) BG64211B1 (ru)
BR (1) BR9709051A (ru)
CA (2) CA2389918A1 (ru)
CO (1) CO4650038A1 (ru)
CZ (1) CZ292825B6 (ru)
DE (1) DE69732966T2 (ru)
DZ (1) DZ2217A1 (ru)
EA (1) EA002272B1 (ru)
ES (1) ES2238079T3 (ru)
GT (1) GT199700043A (ru)
HK (1) HK1019443A1 (ru)
HN (1) HN1997000046A (ru)
HR (1) HRP970227B1 (ru)
HU (1) HUP9902459A3 (ru)
ID (1) ID16856A (ru)
IL (2) IL152083A0 (ru)
IS (1) IS4871A (ru)
MA (1) MA24158A1 (ru)
MY (1) MY132499A (ru)
NO (1) NO312959B1 (ru)
NZ (1) NZ332240A (ru)
OA (1) OA10904A (ru)
PE (1) PE64598A1 (ru)
PL (1) PL329836A1 (ru)
SK (1) SK148298A3 (ru)
TN (1) TNSN97070A1 (ru)
TR (1) TR199802202T2 (ru)
TW (1) TW449585B (ru)
UA (1) UA65536C2 (ru)
UY (1) UY24532A1 (ru)
WO (1) WO1997042174A1 (ru)
YU (1) YU16397A (ru)
ZA (1) ZA973804B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
AU3102697A (en) 1996-06-19 1998-01-07 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1998050367A1 (en) * 1997-05-08 1998-11-12 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
EA200000385A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
BR9813926A (pt) * 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
DK1908463T3 (da) 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101484180B (zh) * 2006-04-21 2014-01-08 森托科尔公司 Cxcl13拮抗剂及其用于治疗炎性疾病的用途
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA3081750A1 (en) 2017-11-06 2019-05-09 Rapt Therapeutics, Inc. Anticancer agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (ru) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
DK0630367T3 (da) * 1992-03-09 2000-09-18 Zeneca Ltd Hidtil ukendte arylindazoler og deres anvendelse som herbicider
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
DE69516298T2 (de) * 1994-10-21 2000-12-28 Elisha Technologies Co. L.L.C., Moberly Korrosionsverhinderndes puffer-system für metallprodukte
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
WO1998050367A1 (en) * 1997-05-08 1998-11-12 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives

Also Published As

Publication number Publication date
NO985095L (no) 1998-12-29
AU1937397A (en) 1997-11-26
BG102946A (en) 1999-11-30
YU16397A (sh) 1999-12-27
IS4871A (is) 1998-10-16
JPH11508284A (ja) 1999-07-21
PL329836A1 (en) 1999-04-12
IL152083A0 (en) 2003-05-29
ES2238079T3 (es) 2005-08-16
NO985095D0 (no) 1998-11-02
CA2252982C (en) 2002-10-08
NO312959B1 (no) 2002-07-22
AP9700975A0 (en) 1997-07-31
HUP9902459A3 (en) 2001-10-29
TW449585B (en) 2001-08-11
CN1217714A (zh) 1999-05-26
BG64211B1 (bg) 2004-05-31
OA10904A (en) 2001-10-11
US6211222B1 (en) 2001-04-03
GT199700043A (es) 1998-10-02
CO4650038A1 (es) 1998-09-03
JP3148254B2 (ja) 2001-03-19
EA002272B1 (ru) 2002-02-28
HRP970227B1 (en) 2002-06-30
DE69732966T2 (de) 2005-09-08
IL126547A0 (en) 1999-08-17
ID16856A (id) 1997-11-13
CA2389918A1 (en) 1997-11-13
AP2001002294A0 (en) 2001-12-31
MY132499A (en) 2007-10-31
KR100339935B1 (ko) 2002-07-18
AP2001002304A0 (en) 2001-12-31
AP0102304A0 (en) 1997-11-03
NZ332240A (en) 2000-07-28
DE69732966D1 (de) 2005-05-12
UY24532A1 (es) 2000-09-29
EP0912521B1 (en) 2005-04-06
US6127398A (en) 2000-10-03
HRP970227A2 (en) 2000-12-31
PE64598A1 (es) 1998-10-26
HN1997000046A (es) 1997-06-26
CZ349298A3 (cs) 1999-09-15
TR199802202T2 (xx) 1999-02-22
CA2252982A1 (en) 1997-11-13
EP0912521A1 (en) 1999-05-06
ZA973804B (en) 1998-11-02
ATE292626T1 (de) 2005-04-15
CN1112359C (zh) 2003-06-25
AP1146A (en) 2003-02-25
WO1997042174A1 (en) 1997-11-13
AP1147A (en) 2003-02-25
AU725576B2 (en) 2000-10-12
AR006906A1 (es) 1999-09-29
HUP9902459A2 (hu) 1999-11-29
UA65536C2 (en) 2004-04-15
TNSN97070A1 (fr) 2005-03-15
HK1019443A1 (en) 2000-02-11
CZ292825B6 (cs) 2003-12-17
KR20000010751A (ko) 2000-02-25
MA24158A1 (fr) 1997-12-31
BR9709051A (pt) 1999-08-03
IL126547A (en) 2003-03-12
SK148298A3 (en) 2000-02-14
CN1422849A (zh) 2003-06-11
DZ2217A1 (fr) 2002-12-03

Similar Documents

Publication Publication Date Title
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
EA199900183A1 (ru) Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
EA199801047A1 (ru) Замешенные призводные инлазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
EA200200360A1 (ru) Производные пурина
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
MY132642A (en) Naphthyridine derivatives
EA200001122A1 (ru) Ингибиторы синтазы оксида азота
EA200401378A1 (ru) N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
EA199900022A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
AU562377B2 (en) 1,1-diphenyl-propanol-derivatives
GB0114699D0 (en) Organic compounds
EA200100953A1 (ru) L-арабино-дисахариды антрациклинов, способы их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU